MCID: VGN017
MIFTS: 48

Vaginal Cancer

Categories: Rare diseases, Cancer diseases, Reproductive diseases

Aliases & Classifications for Vaginal Cancer

MalaCards integrated aliases for Vaginal Cancer:

Name: Vaginal Cancer 12 49 40 14
Vaginal Neoplasms 41 69
Vaginal Malignant Epithelial Tumor 55
Malignant Neoplasm of Vagina 12
Malignant Vaginal Neoplasm 69
Malignant Tumor of Vagina 12
Malignant Vaginal Tumor 12
Neoplasm of Vagina 12
Vaginal Carcinoma 55
Vaginal Neoplasia 69
Vaginal Neoplasm 28
Vagina Carcinoma 69
Vagina Neoplasm 12
Vaginal Tumor 12

Classifications:



External Ids:

Disease Ontology 12 DOID:119
ICD10 32 C52
ICD9CM 34 184.0
MeSH 41 D014625
NCIt 46 C3437 C7410
Orphanet 55 ORPHA180247
UMLS via Orphanet 70 C0262659
ICD10 via Orphanet 33 C52

Summaries for Vaginal Cancer

MedlinePlus : 40 Vaginal cancer is a rare type of cancer. It is more common in women 60 and older. You are also more likely to get it if you have had a human papillomavirus (HPV) infection or if your mother took diethylstilbestrol (DES) when she was pregnant. Doctors prescribed DES in the 1950's to prevent miscarriages. You are also at higher risk if you have had abnormal cells in the vagina, cervix, or uterus. It often doesn't have early symptoms. However, see your doctor if you notice Bleeding that is not your period A vaginal lump Pelvic pain A Pap test can find abnormal cells that may be cancer. Vaginal cancer can often be cured in its early stages. Treatment might include surgery, radiation therapy, and chemotherapy. NIH: National Cancer Institute

MalaCards based summary : Vaginal Cancer, also known as vaginal neoplasms, is related to vaginal disease and vaginitis, and has symptoms including vaginal pruritus and pelvic pain. An important gene associated with Vaginal Cancer is HLA-G (Major Histocompatibility Complex, Class I, G), and among its related pathways/superpathways is Antigen Presentation- Folding, assembly and peptide loading of class I MHC. The drugs Gardasil and Octreotide have been mentioned in the context of this disorder. Affiliated tissues include the vagina, cervix and uterus, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A female reproductive system cancer that is located in the vagina.

Wikipedia : 72 Vaginal cancer is any type of cancer that forms in the tissues of the vagina. Primary vaginal cancer is... more...

Related Diseases for Vaginal Cancer

Graphical network of the top 20 diseases related to Vaginal Cancer:



Diseases related to Vaginal Cancer

Symptoms & Phenotypes for Vaginal Cancer

UMLS symptoms related to Vaginal Cancer:


vaginal pruritus, pelvic pain

GenomeRNAi Phenotypes related to Vaginal Cancer according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00173-A 9.23 MAPK8IP1 MYLK2
2 Decreased viability GR00221-A-1 9.23 MYLK2
3 Decreased viability GR00221-A-2 9.23 MYLK2
4 Decreased viability GR00221-A-4 9.23 MAPK8IP1 MYLK2
5 Decreased viability GR00301-A 9.23 MAPK8IP1
6 Decreased viability GR00342-S-3 9.23 MAPK8IP1

Drugs & Therapeutics for Vaginal Cancer

FDA approved drugs:

# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Gardasil 17 45 quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Merck June 2006

Drugs for Vaginal Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 127)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Octreotide Approved, Investigational Phase 3 83150-76-9 6400441 383414
2
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
3
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
4
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
5
Ondansetron Approved Phase 3 99614-02-5 4595
6
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 3 53-43-0 9860744
7 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
8 Liver Extracts Phase 3,Phase 2,Phase 1
9 Vaccines Phase 3,Phase 2,Phase 1
10 Antineoplastic Agents, Hormonal Phase 3
11 Gastrointestinal Agents Phase 3,Phase 1
12 Adjuvants, Anesthesia Phase 3
13 Analgesics Phase 3,Phase 2
14 Analgesics, Opioid Phase 3
15 Anesthetics Phase 3
16 Anesthetics, General Phase 3
17 Anesthetics, Intravenous Phase 3
18 Central Nervous System Depressants Phase 3
19 Narcotics Phase 3
20 Peripheral Nervous System Agents Phase 3,Phase 2
21 Dermatologic Agents Phase 3,Phase 2
22 Adjuvants, Immunologic Phase 3,Phase 1
23 Neurotransmitter Agents Phase 3,Phase 2
24 Psychotropic Drugs Phase 3,Phase 2
25 Anti-Anxiety Agents Phase 3
26 Antiemetics Phase 3
27 Antipruritics Phase 3
28 Antipsychotic Agents Phase 3
29 Autonomic Agents Phase 3
30 Emetics Phase 3
31
Serotonin Phase 3 50-67-9 5202
32 Serotonin Agents Phase 3
33 Serotonin Antagonists Phase 3
34 Tranquilizing Agents Phase 3
35 Cola Nutraceutical Phase 3,Phase 2,Phase 1
36 DHEA (Dehydroepiandrosterone) Nutraceutical Phase 3
37
Indinavir Approved Phase 2 150378-17-9 5362440
38
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
39
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
40
Fludarabine Approved Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
41
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
42
Mycophenolate mofetil Approved, Investigational Phase 2 128794-94-5 5281078
43
Mycophenolic acid Approved Phase 2 24280-93-1 446541
44
Bevacizumab Approved, Investigational Phase 2 216974-75-3
45
Aldesleukin Approved Phase 1, Phase 2 110942-02-4, 85898-30-2
46
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
47
Vidarabine Approved, Investigational Phase 1, Phase 2 24356-66-9 21704 32326
48 Fondaparinux Approved, Investigational Phase 2 104993-28-4
49
Bupropion Approved Phase 2 34911-55-2, 34841-39-9 444
50
Dopamine Approved Phase 2 51-61-6, 62-31-7 681

Interventional clinical trials:

(show top 50) (show all 96)

# Name Status NCT ID Phase Drugs
1 Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer Unknown status NCT01087268 Phase 3
2 Pelvic Drains After Radical Hysterectomy in Treating Patients With Uterine, Cervical, or Vaginal Cancer Completed NCT00003267 Phase 3
3 Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED) Completed NCT00092521 Phase 3
4 A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006) Completed NCT01047345 Phase 3
5 Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) Completed NCT00543543 Phase 3
6 A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019) Completed NCT00090220 Phase 3
7 GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046) Completed NCT01245764 Phase 3
8 Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis Completed NCT00033605 Phase 3 octreotide acetate
9 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
10 Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004) Recruiting NCT03158220 Phase 3
11 Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation Active, not recruiting NCT01536392 Phase 3 Granisetron;Ondansetron
12 A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002) Active, not recruiting NCT00943722 Phase 3
13 Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms Active, not recruiting NCT01376349 Phase 3 prasterone
14 Nutritional Supplements in Improving Quality of Life During First-Line Chemotherapy in Patients With Metastatic Gynecological Cancer Unknown status NCT00905658 Phase 2
15 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
16 Triapine, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer or Vaginal Cancer Completed NCT00941070 Phase 2 triapine;cisplatin
17 Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cervical or Vaginal Cancer Completed NCT00002562 Phase 2 paclitaxel
18 Peripheral Stem Cell Transplant, White Blood Cell Infusions, Chemotherapy, and Radiation Therapy in Treating Patients With Recurrent Metastatic Cervical or Vaginal Cancer Completed NCT00005941 Phase 2 cyclosporine;fludarabine phosphate;mycophenolate mofetil
19 Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers Completed NCT00545792 Phase 2 Avastin
20 Intensity Modulated Radiation Therapy - Gyne Cancer (GY03.2) Completed NCT00188578 Phase 1, Phase 2
21 Effectiveness of an Individualized Symptom Education Program (ISEP) Completed NCT00275353 Phase 2
22 T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers Completed NCT02280811 Phase 1, Phase 2 Fludarabine;Cyclophosphamide;Aldesleukin
23 Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers Completed NCT01585428 Phase 2 Fludarabine;Cyclophosphamide;Aldesleukin
24 A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED) Completed NCT00551187 Phase 2
25 Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001) Completed NCT00520598 Phase 2 Comparator: V505 formulation 2;Comparator: V505 formulation 2
26 Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer Completed NCT00381888 Phase 2 fondaparinux sodium
27 Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies Completed NCT01079832 Phase 2
28 Radiation Therapy and Cisplatin With or Without Triapine in Treating Patients With Newly Diagnosed Stage IB2, II, or IIIB-IVA Cervical Cancer or Stage II-IVA Vaginal Cancer Recruiting NCT02466971 Phase 2 Cisplatin;Triapine
29 Examining the Role of Transrectal High Intensity Focused Ultrasound (HIFU) in Rectal Pelvic Cancer Recruiting NCT01097239 Phase 1, Phase 2
30 Image-Guided Gynecologic Brachytherapy Recruiting NCT02993900 Phase 2
31 Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer Recruiting NCT01764802 Phase 2
32 Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer Recruiting NCT03180294 Phase 2 Bupropion Hydrochloride
33 Image-Guided Gynecologic Brachytherapy Active, not recruiting NCT01399658 Phase 2
34 Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma Not yet recruiting NCT03220009 Phase 2
35 Study of Velcade and Irinotecan in Advanced Cervical, Vulvar, or Vaginal Cancer Terminated NCT00106262 Phase 2 Velcade (bortezomib);Irinotecan
36 Broad Spectrum HPV Vaccine Tolerability, Immunogenicity, and Efficacy Study (V502-003) Withdrawn NCT00365443 Phase 2
37 Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions Unknown status NCT00066404 Phase 1
38 Vinorelbine and Paclitaxel Plus Radiation Therapy in Treating Patients With Advanced Cancer Arising in the Pelvis Completed NCT00002949 Phase 1 paclitaxel;vinorelbine tartrate
39 Topotecan in Treating Patients With Gynecologic Cancer That Cannot Be Removed by Surgery Completed NCT00842452 Phase 1 topotecan hydrochloride
40 Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer Completed NCT00287885 Phase 1 docetaxel
41 Broad Spectrum HPV Vaccine Dose Escalation Study (V502-002) Completed NCT00851643 Phase 1
42 Phase I Study of Intravenous Triapine (IND # 68338) in Combination With Pelvic Radiation Therapy With or Without Weekly Intravenous Cisplatin Chemotherapy for Locally Advanced Cervical, Vaginal, or Pelvic Gynecologic Malignancies Completed NCT00335998 Phase 1 triapine;cisplatin
43 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
44 Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer Completed NCT01652794 Phase 1 carboplatin;gemcitabine hydrochloride
45 Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer Completed NCT00005842 Phase 1 tipifarnib
46 Gene Therapy in Treating Patients With Cancer Completed NCT00004178 Phase 1
47 MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma Completed NCT00020579 Phase 1 entinostat
48 RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma Completed NCT00101972 Phase 1
49 Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma Completed NCT00083213 Phase 1
50 Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma Completed NCT00082823 Phase 1

Search NIH Clinical Center for Vaginal Cancer

Cochrane evidence based reviews: vaginal neoplasms

Genetic Tests for Vaginal Cancer

Genetic tests related to Vaginal Cancer:

# Genetic test Affiliating Genes
1 Vaginal Neoplasm 28

Anatomical Context for Vaginal Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Vaginal Cancer:

18
The Vagina

MalaCards organs/tissues related to Vaginal Cancer:

38
Cervix, Uterus, Testes, Liver, T Cells, Brain, Prostate

Publications for Vaginal Cancer

Articles related to Vaginal Cancer:

(show top 50) (show all 133)
# Title Authors Year
1
Abdominal radical trachelectomy for vaginal cancer - A case report. ( 28664182 )
2017
2
Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of vulvar cancer and vaginal cancer. ( 29159773 )
2017
3
Radiotherapy for vaginal cancer: a multi-institutional survey study of the Japanese Radiation Oncology Study Group. ( 29086206 )
2017
4
Descriptive epidemiological study of vaginal cancer using data from the Osaka Japan population-based cancer registry: Long-term analysis from a clinical viewpoint. ( 28796063 )
2017
5
MR Imaging of Vulvar andA Vaginal Cancer. ( 28668156 )
2017
6
Sentinel lymph node mapping with indocyanine green in vaginal cancer. ( 28541627 )
2017
7
Definitive treatment of primary vaginal cancer with radiotherapy: multi-institutional retrospective study of the Korean Radiation Oncology Group (KROG 12-09). ( 26768782 )
2016
8
Treatment of early stage vaginal cancer with EBRT and MRI-based intracavitary brachytherapy: A retrospective case review. ( 27536721 )
2016
9
High-grade vaginal intraepithelial neoplasia and risk of progression to vaginal cancer: a multicentre study of the Italian Society of Colposcopy and Cervico-Vaginal Pathology (SICPCV). ( 27010135 )
2016
10
Prognostic impact of clinical tumor size on overall survival for subclassifying stages I and II vaginal cancer: A SEER analysis. ( 26970567 )
2016
11
Breast metastasis from vaginal cancer. ( 27444140 )
2016
12
Role of Radical Surgery in Early Stages of Vaginal Cancer-Our Experience. ( 27327154 )
2016
13
Outcomes with image-based interstitial brachytherapy for vaginal cancer. ( 27321150 )
2016
14
Prognostic Factors in Primary Vaginal Cancer: A Single Institute Experience and Review of Literature. ( 27486283 )
2016
15
Brachytherapy improves survival in primary vaginal cancer. ( 27036631 )
2016
16
Vaginal cancer possibly caused by pessary and immunocompromised condition: Multiple risk factors may influence vaginal cancer development. ( 26914159 )
2016
17
Radical Hysterectomy and Total Abdominal Vaginectomy for Primary Vaginal Cancer. ( 26825828 )
2016
18
The impact of FDG-PET/CT in the management of patients with vulvar and vaginal cancer. ( 26790773 )
2016
19
Vulvar and Vaginal Cancer, Vulvar Intraepithelial Neoplasia 3 and Vaginal Intraepithelial Neoplasia 3: Experience of a Referral Institute. ( 27430086 )
2016
20
Vaginal Intraepithelial Neoplasia: Histopathological Upgrading of Lesions and Evidence of Occult Vaginal Cancer. ( 26461231 )
2015
21
Management of Vaginal Cancer. ( 26411952 )
2015
22
Image-based multichannel vaginal cylinder brachytherapy for vaginal cancer. ( 25456026 )
2015
23
Primary vaginal cancer: role of MRI in diagnosis, staging and treatment. ( 25966291 )
2015
24
Vulval and vaginal cancer in pregnancy. ( 26526939 )
2015
25
Patterns of care and brachytherapy boost utilization for vaginal cancer in the United States. ( 25413431 )
2015
26
LASER VAPORIZATION IN VULVAR INTRAEPITHELIAL NEOPLASIA (VIN), VAGINAL INTRAEPITHELIAL NEOPLASIA (VAIN) AND CONDYLOMATA ACUMINATA: IGCS-0093 Vulvar and Vaginal Cancer. ( 25955950 )
2015
27
Definitive radiotherapy for primary vaginal cancer: correlation between treatment patterns and recurrence rate. ( 25614068 )
2015
28
Sarcoid-like reaction mimicking vaginal cancer recurrence. ( 26420533 )
2015
29
Staging for vaginal cancer. ( 25847318 )
2015
30
PROGNOSTIC SIGNIFICANCE OF TUMOR SIZE IN SQUAMOUS CELL CARCINOMA OF THE VULVA: IGCS-0107 Vulvar and Vaginal Cancer. ( 25955951 )
2015
31
HDR brachytherapy for the reirradiation of cervical and vaginal cancer: Analysis of efficacy and dosage delivered to organs at risk. ( 24161366 )
2014
32
Vaginal cancer in a patient with complicated prolapse history: a case report. ( 25181382 )
2014
33
Successful pregnancy after uterus-sparing chemoradiation therapy for vaginal cancer. ( 25432539 )
2014
34
Human papillomavirus genotype prevalence in invasive vaginal cancer from a registry-based population. ( 24785610 )
2014
35
Prognostic factors for curative pelvic exenterations in patients with recurrent uterine cervical or vaginal cancer. ( 25254565 )
2014
36
Effect of ageing on cervical or vaginal cancer in Swedish women previously treated for cervical intraepithelial neoplasia grade 3: population based cohort study of long term incidence and mortality. ( 24423603 )
2014
37
Improved survival in p16-positive vaginal cancers across all tumor stages but no correlation with MIB-1. ( 25319982 )
2014
38
Uterine prolapse complicated by vaginal cancer: a case report and literature review. ( 24481208 )
2014
39
Targeting human papillomavirus to reduce the burden of cervical, vulvar and vaginal cancer and pre-invasive neoplasia: establishing the baseline for surveillance. ( 24505474 )
2014
40
Adoption and impact of concurrent chemoradiation therapy for vaginal cancer: A National Cancer Data Base (NCDB) study. ( 25281493 )
2014
41
Vaginal cancer: the experience from 2 large academic centers during a 15-year period. ( 23609592 )
2013
42
Does histologic type correlate to outcome after pelvic exenteration for cervical and vaginal cancer? ( 23212765 )
2013
43
Acr appropriateness Criteria management of vaginal cancer. ( 24575547 )
2013
44
HLA-G 3'UTR polymorphisms in high grade and invasive cervico-vaginal cancer. ( 23228396 )
2013
45
Concurrent chemoradiation for vaginal cancer. ( 23762284 )
2013
46
Urethral dosimetry and toxicity with high-dose-rate interstitial brachytherapy for vaginal cancer. ( 23453679 )
2013
47
Dosimetric comparison of multichannel with one single-channel vaginal cylinder for vaginal cancer treatments with high-dose-rate brachytherapy. ( 24080298 )
2013
48
A case of vaginal cancer with uterine prolapse. ( 25371880 )
2013
49
Is there a place for sentinel technique in treatment of vaginal cancer?: feasibility, clinical experience, and results. ( 24177255 )
2013
50
Vaginal cancer with multiple liver and pulmonary metastases that achieved long-term survival. ( 24396823 )
2013

Variations for Vaginal Cancer

Cosmic variations for Vaginal Cancer:

9 (show top 50) (show all 57)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM43896 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.818G>C p.R273P 5
2 COSM43662 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.868C>A p.R290S 5
3 COSM10662 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 5
4 COSM10659 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.817C>T p.R273C 5
5 COSM44029 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.550G>A p.D184N 5
6 COSM45259 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.301A>T p.K101* 5
7 COSM43660 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.719G>T p.S240I 5
8 COSM11483 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.848G>A p.R283H 5
9 COSM10705 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.586C>T p.R196* 5
10 COSM10648 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.524G>A p.R175H 5
11 COSM45507 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.806G>C p.S269T 5
12 COSM10725 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.701A>G p.Y234C 5
13 COSM11356 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.726C>G p.C242W 5
14 COSM46185 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.775G>C p.D259H 5
15 COSM10889 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.536A>G p.H179R 5
16 COSM43878 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.427G>A p.V143M 5
17 COSM43624 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.875A>G p.K292R 5
18 COSM10749 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.830G>T p.C277F 5
19 COSM25844 STK11 cervix,NS,carcinoma,squamous cell carcinoma c.647C>T p.S216F 5
20 COSM29465 STK11 cervix,NS,carcinoma,squamous cell carcinoma c.320A>G p.H107R 5
21 COSM3734673 STK11 cervix,NS,carcinoma,squamous cell carcinoma c.597G>C p.E199D 5
22 COSM29464 STK11 cervix,NS,carcinoma,squamous cell carcinoma c.169G>T p.E57* 5
23 COSM5089 PTEN cervix,NS,carcinoma,squamous cell carcinoma c.517C>T p.R173C 5
24 COSM5945791 PTEN cervix,NS,carcinoma,squamous cell carcinoma c.65A>G p.D22G 5
25 COSM773 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.3129G>T p.M1043I 5
26 COSM12458 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.1634A>C p.E545A 5
27 COSM763 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.1633G>A p.E545K 5
28 COSM760 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.1624G>A p.E542K 5
29 COSM766 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.1636C>A p.Q546K 5
30 COSM775 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.3140A>G p.H1047R 5
31 COSM17442 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.1624G>C p.E542Q 5
32 COSM5878662 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.1579G>A p.D527N 5
33 COSM1168056 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.3145G>T p.G1049C 5
34 COSM12459 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.1637A>G p.Q546R 5
35 COSM580 NRAS cervix,NS,carcinoma,squamous cell carcinoma c.181C>A p.Q61K 5
36 COSM120958 NFE2L2 cervix,NS,carcinoma,squamous cell carcinoma c.235G>C p.E79Q 5
37 COSM521 KRAS cervix,NS,carcinoma,squamous cell carcinoma c.35G>A p.G12D 5
38 COSM517 KRAS cervix,NS,carcinoma,squamous cell carcinoma c.34G>A p.G12S 5
39 COSM518 KRAS cervix,NS,carcinoma,squamous cell carcinoma c.34G>C p.G12R 5
40 COSM551 KRAS cervix,NS,carcinoma,squamous cell carcinoma c.182A>C p.Q61P 5
41 COSM555 KRAS cervix,NS,carcinoma,squamous cell carcinoma c.183A>T p.Q61H 5
42 COSM552 KRAS cervix,NS,carcinoma,squamous cell carcinoma c.182A>G p.Q61R 5
43 COSM483 HRAS cervix,NS,carcinoma,squamous cell carcinoma c.35G>T p.G12V 5
44 COSM480 HRAS cervix,NS,carcinoma,squamous cell carcinoma c.34G>A p.G12S 5
45 COSM497 HRAS cervix,NS,carcinoma,squamous cell carcinoma c.181C>G p.Q61E 5
46 COSM499 HRAS cervix,NS,carcinoma,squamous cell carcinoma c.182A>G p.Q61R 5
47 COSM715 FGFR3 cervix,NS,carcinoma,squamous cell carcinoma c.746C>G p.S249C 5
48 COSM49174 FGFR2 cervix,NS,carcinoma,squamous cell carcinoma c.289G>A p.A97T 5
49 COSM49175 FGFR2 cervix,NS,carcinoma,squamous cell carcinoma c.1976A>T p.K659M 5
50 COSM5730 CTNNB1 cervix,NS,carcinoma,squamous cell carcinoma c.122C>A p.T41N 5

Expression for Vaginal Cancer

Search GEO for disease gene expression data for Vaginal Cancer.

Pathways for Vaginal Cancer

Pathways related to Vaginal Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.02 HLA-G SAR1B

GO Terms for Vaginal Cancer

Cellular components related to Vaginal Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ER to Golgi transport vesicle membrane GO:0012507 8.62 HLA-G SAR1B

Biological processes related to Vaginal Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 8.62 HLA-G SAR1B

Sources for Vaginal Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....